Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 511-518

  Yonezawa, Takayuki ^a,b   Hasegawa, Shin Ichi ^b   Asai, Midori ^b   Ninomiya, Tadashi ^c   Sasaki, Toshinori ^b   Cha, Byung Yoon ^b   Teruya, Toshiaki ^b   Ozawa, Hidehiro ^c   Yagasaki, Kazumi ^a,d   Nagai, Kazuo ^b   Woo, Je Tae ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c MATSUMOTO DENTAL UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Bone resorption; Harmine; Osteoclast; Osteoporosis

Indexed keywords

COLECALCIFEROL; COLONY STIMULATING FACTOR 1; HARMALINE; HARMALOL; HARMAN; HARMINE; HARMOL; I KAPPA B ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; PROTEIN C FOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT C1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MITOSIS INHIBITION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DOWN-REGULATION; FEMALE; HARMINE; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOCLASTS; OVARIECTOMY; RANK LIGAND; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78651087056     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.048     Document Type: Article

References (25)

1. S.J. Ajizian, B.K. English, and E.A. Meals Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma J. Infect. Dis. 179 1999 939 944
2. J.R.F. Allen, and B.R. Holmstedt The simple beta-carboline alkaloids Phytochemistry 19 1980 1573 1582
3. J.R. Arron, M.M. Winslow, A. Polleri, C.-P. Chang, H. Wu, X. Gao, J.R. Neilson, L. Chen, J.J. Heit, S.K. Kim, N. Yamasaki, T. Miyakawa, U. Francke, I.A. Graef, and G.R. Crabtree NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 Nature 441 2006 595 600
4. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S.C. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315
5. H. Berrougui, C. Martin-Cordero, A. Khalil, M. Hmamouchi, A. Ettaib, E. Marhuenda, and M.D. Herrera Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta Pharmacol. Res. 54 2006 150 157
6. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
7. R. Cao, W. Peng, Z. Wang, and A. Xu β-Carboline alkaloids: biochemical and pharmacological functions Curr. Med. Chem. 14 2007 479 500
8. D. Farzin, and N. Mansouri Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test Eur. Neuropsychopharmacol. 16 2006 324 328
9. G.J. Feng, H.S. Goodridge, M.M. Harnett, X.Q. Wei, A.V. Nikolaev, A.P. Higson, and F.Y. Liew Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase J. Immunol. 163 1999 6403 6412
10. X. Feng RANKing intracellular signaling in osteoclasts IUBMB Life 57 2005 389 395
11. Y. Gwack, S. Sharma, J. Nardone, B. Tanasa, A. Iuga, S. Srikanth, H. Okamura, D. Bolton, S. Feske, P.G. Hogan, and A. Rao A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT Nature 441 2006 646 650
12. B. Hammerle, C. Elizalde, J. Galceran, W. Becker, and F.J. Tejedor The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications J. Neural Transm. Suppl. 67 2003 129 137
13. A.L. Harvey Natural products in drug discovery Drug Discov. Today 13 2008 894 901
14. H. Hotokezaka, E. Sakai, K. Kanaoka, K. Saito, K.-I. Matsuo, H. Kitaura, N. Yoshida, and K. Nakayama U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells J. Biol. Chem. 277 2002 47366 47372
15. S.M. Husbands, R.A. Glennon, S. Gorgerat, R. Gough, R. Tyacke, J. Crosby, D.J. Nutt, J.W. Lewis, and A.L. Hudson β-Carboline binding to imidazoline receptors Drug Alcohol Depend. 64 2001 203 208
16. K.S. Lam New aspects of natural products in drug discovery Trends Microbiol. 15 2007 279 289
17. C.A. O'Brien, I. Gubrij, S.C. Lin, R.L. Saylors, and S.C. Manolagas STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274 1999 19301 19308
18. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
19. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr. Rev. 20 1999 345 357 (Pubitemid 30649812)
20. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J.-I. Inoue, E.F. Wagner, T.W. Mak, T. Kodama, and T. Taniguchi Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev. Cell 3 2002 889 901
21. H. Waki, K.W. Park, N. Mitro, L. Pei, R. Damoiseaux, D.C. Wilpitz, K. Reue, E. Saez, and P. Tontonoz The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression Cell Metab. 5 2007 357 370
22. J.T. Woo, H. Nakagawa, M. Notoya, T. Yonezawa, N. Udagawa, I.S. Lee, M. Ohnishi, H. Hagiwara, and K. Nagai Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts Biol. Pharm. Bull. 27 2004 504 509
23. Q.W. Xie, Y. Kashiwabara, and C. Nathan Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase J. Biol. Chem. 269 1994 4705 4708 (Pubitemid 24239438)
24. T. Yonezawa, S.I. Hasegawa, J.Y. Ahn, B.Y. Cha, T. Teruya, H. Hagiwara, K. Nagai, and J.-T. Woo Tributyltin and triphenyltin inhibit osteoclast differentiation through a retinoic acid receptor-dependent signaling pathway Biochem. Biophys. Res. Commun. 355 2007 10 15
25. Q. Zhao, X. Wang, Y. Liu, A. He, and R. Jia NFATc1: functions in osteoclasts Int. J. Biochem. Cell Biol. 42 2010 576 579